Cardlytics (NASDAQ:CDLX) Upgraded at Craig Hallum

Cardlytics (NASDAQ:CDLX) was upgraded by equities research analysts at Craig Hallum from a “hold” rating to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts have also commented on CDLX. Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $7.00 to $5.00 in a research report on Friday, August 16th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday. Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $18.00 to $5.00 in a research report on Thursday, August 8th. Evercore ISI assumed coverage on shares of Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective for the company. Finally, Bank of America lowered Cardlytics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Cardlytics has a consensus rating of “Hold” and a consensus price target of $6.92.

Cardlytics Trading Up 10.1 %

Shares of NASDAQ:CDLX traded up $0.41 during midday trading on Wednesday, hitting $4.48. 921,946 shares of the stock were exchanged, compared to its average volume of 1,238,457. The business’s 50-day moving average price is $3.68 and its 200 day moving average price is $6.76. Cardlytics has a 12 month low of $2.89 and a 12 month high of $20.52. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a market capitalization of $223.28 million, a price-to-earnings ratio of -1.21 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The business had revenue of $69.64 million for the quarter, compared to analysts’ expectations of $75.39 million. During the same period in the prior year, the business posted ($0.57) earnings per share. The firm’s revenue was down 9.2% on a year-over-year basis. Analysts predict that Cardlytics will post -1.72 earnings per share for the current year.

Insider Activity

In related news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Scott A. Hill bought 40,000 shares of Cardlytics stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $143,200. The disclosure for this purchase can be found here. In the last quarter, insiders sold 43,573 shares of company stock valued at $151,612. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CDLX. Canton Hathaway LLC increased its holdings in shares of Cardlytics by 95.7% during the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Cardlytics in the third quarter worth approximately $45,000. Creative Planning grew its holdings in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after buying an additional 7,721 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Cardlytics during the second quarter valued at approximately $107,000. Finally, Quest Partners LLC raised its holdings in Cardlytics by 160.4% in the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after acquiring an additional 11,061 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.